Nanoform Finland Plc (NANOFS)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 7.500 |
|---|---|
| 52-week range | 4.145 – 13.780 |
| Return, 1 month / 3 months | −24.2% / −25.3% |
| Return, 1 year / 3 years | −41.3% / −61.3% |
| Trend | Below its 200-day average |
| RSI (14) | 29 |
| Volatility (1 year) | 80.1% |
| Worst drawdown (1 year) | -65.5% |
| Average daily value traded | 0.11M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nanoform Finland is a pharmaceutical technology company based in Helsinki, Finland. It provides nanoparticle engineering services that make drug compounds easier to dissolve and absorb in the body, working with pharmaceutical and biotechnology companies that need to improve how their medicines are formulated and delivered. Its technology is applied to small molecule drugs and other active ingredients, and the company supports partners through formulation development and production of nanoformed particles for clinical and commercial use.
On this site Nanoform Finland Plc appears as a stock on the Nasdaq Stockholm (Sweden), code NANOFS, with prices in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nanoform Finland Plc (NANOFS) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 7.500 on 27 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 624 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 41.3% and over the last three months it fell 25.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.7% | ||
| From 52-week high | -41.8% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -25.3% | ||
| 6-month return | 43.7% | ||
| 12-month return, skipping the last month | -22.6% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 80.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -65.5% | ||
| Liquidity | 31 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.11M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −5.1% |
|---|---|
| 1 month | −24.2% |
| 3 months | −25.3% |
| 6 months | +43.7% |
| 1 year | −41.3% |
| 3 years | −61.3% |
| 5 years | −90.4% |
Signals
| 50-day / 200-day average | 9.561 / 8.687 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.349 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.